The Food and Drug Administration (FDA) is classifying the high throughput DNA sequencing for hereditary cancer predisposition assessment test system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the high throughput DNA sequencing for hereditary cancer predisposition assessment test system. We are taking this action because we have determined that classifying the dev

Original title: “Medical Devices; Immunology and Microbiology Devices; Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System”

morphologic and immunophenotypic spectrum of 11 gastric cancers with elevated serum alpha fetoprotein emphasis on hepatoid or enteroblastic differentiation

Original title: “Morphologic and Immunophenotypic Spectrum of 11 Gastric Cancers with Elevated Serum Alpha-Fetoprotein: Emphasis on Hepatoid or Enteroblastic Differentiation.”

global trends in gastric cancer burden among adolescents and young adults a population based observational study using gbd 2021 data

Original title: “Global trends in gastric cancer burden among adolescents and young adults: A population-based observational study using GBD 2021 data.”

underestimation of subserosal invasion in early gastric cancer like advanced gastric carcinoma with focal enteroblastic differentiation a case report

Original title: “Underestimation of Subserosal Invasion in Early Gastric Cancer-Like Advanced Gastric Carcinoma With Focal Enteroblastic Differentiation: A Case Report.”

postoperative adjuvant treatment decision for early epstein barr virus associated gastric cancer

Original title: “Postoperative Adjuvant Treatment Decision for Early Epstein-Barr Virus-Associated Gastric Cancer.”

non exposure lecs clean net for gastric cancer long term outcomes of a function preserving strategy with selective nodal assessment

Original title: “Non-exposure LECS (CLEAN-NET) for gastric cancer: long-term outcomes of a function-preserving strategy with selective nodal assessment.”

unfavorable outcomes of t3n0 remnant gastric cancer after distal gastrectomy

Original title: “Unfavorable Outcomes of T3N0 Remnant Gastric Cancer After Distal Gastrectomy.”

zolbetuximab research progress and prospects in the treatment of gastric and gastroesophageal junction cancer targeting claudin 18 2

Original title: “Zolbetuximab: research progress and prospects in the treatment of gastric and gastroesophageal junction cancer targeting claudin 18.2.”